Pharmacology Pharmacokinetics and Drug Metabolism Questions and Answers 1 — Questions and Answers
Question 1: A patient is being treated with a drug that is a known substrate for the CYP3A4 enzyme. If the patient starts taking a new medication that is a potent inducer of CYP3A4, what is the most likely pharmacokinetic consequence?
- Increased plasma concentration of the first drug, leading to potential toxicity.
- Decreased plasma concentration of the first drug, leading to potential therapeutic failure. (Correct answer)
- No change in the plasma concentration of the first drug.
- An increase in the half-life of the first drug.
Correct answer: Decreased plasma concentration of the first drug, leading to potential therapeutic failure.
CYP3A4 inducers increase the metabolic activity of the enzyme. This leads to a faster breakdown of the substrate drug, resulting in lower plasma concentrations and potentially reducing its therapeutic effect. [20, 28]
Question 2: A 500 mg dose of a drug is administered intravenously, resulting in an initial plasma concentration of 25 mg/L. What is the apparent volume of distribution (Vd) for this drug?
- 10 L
- 15 L
- 20 L (Correct answer)
- 25 L
Correct answer: 20 L
The volume of distribution (Vd) is calculated by dividing the dose administered by the initial plasma concentration (Vd = Dose / C0). In this case, Vd = 500 mg / 25 mg/L = 20 L. [26]
Question 3: Which of the following statements accurately describes Phase II metabolism?
- It typically involves oxidation, reduction, or hydrolysis reactions. [1, 2]
- It often produces metabolites that are more pharmacologically active than the parent drug.
- It involves conjugation reactions that increase the water solubility of a drug for excretion. [7] (Correct answer)
- It is the primary mechanism of the first-pass effect.
Correct answer: It involves conjugation reactions that increase the water solubility of a drug for excretion. [7]
Phase II metabolism involves conjugation reactions, where an endogenous substrate (like glucuronic acid, sulfate, or an amino acid) is attached to the drug or its Phase I metabolite. This process generally increases the molecule's polarity and water solubility, facilitating its renal or biliary excretion. [1, 7]
Question 4: A patient with severe liver cirrhosis is administered a drug that is primarily eliminated through hepatic metabolism. How would this patient's condition most likely affect the drug's half-life (t1/2)?
- The half-life will be significantly shortened.
- The half-life will be unchanged.
- The half-life will be significantly prolonged. [3] (Correct answer)
- The half-life will become dose-dependent.
Correct answer: The half-life will be significantly prolonged. [3]
Liver cirrhosis impairs the liver's metabolic capacity. Since the drug is primarily eliminated by the liver, its clearance will be reduced. A decrease in clearance leads to a prolongation of the elimination half-life, increasing the risk of drug accumulation and toxicity. [3, 15]
Question 5: The 'first-pass effect' primarily refers to the pre-systemic metabolism of an orally administered drug that occurs in which two organs?
- Kidney and lungs
- Liver and small intestine [13, 18] (Correct answer)
- Stomach and spleen
- Brain and heart
Correct answer: Liver and small intestine [13, 18]
The first-pass effect, or first-pass metabolism, describes the process where a drug administered orally is absorbed from the gastrointestinal tract and transported via the portal vein to the liver. Both the intestinal wall and the liver contain enzymes that can metabolize the drug before it reaches systemic circulation, thereby reducing its bioavailability. [5, 13, 18]
Question 6: Therapeutic Drug Monitoring (TDM) is most clinically useful for drugs that exhibit which of the following characteristics?
- A wide therapeutic index and predictable pharmacokinetics.
- A narrow therapeutic range and significant pharmacokinetic variability. [4, 8] (Correct answer)
- High protein binding and a short half-life.
- Metabolism exclusively through Phase II reactions.
Correct answer: A narrow therapeutic range and significant pharmacokinetic variability. [4, 8]
TDM is most valuable for drugs where there is a small margin between the effective concentration and the toxic concentration (a narrow therapeutic range). It is also crucial when there is high inter-individual variability in how the drug is absorbed, distributed, metabolized, and excreted, making standardized dosing unreliable. [4, 8, 16]
Pharmacology Pharmacokinetics and Drug Metabolism Questions and Answers 1
A patient is being treated with a drug that is a known substrate for the CYP3A4 enzyme.
If the patient starts taking a new medication that is a potent inducer of CYP3A4, what is the most likely pharmacokinetic consequence?